Prostate cancer patients improve survival with innovative treatment
Treatment with apalutamide showed a 14-month improvement in median overall survival in patients with non-metastatic castration-resistant prostate cancer. Results presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in…
See more Prostate cancer patients improve survival with innovative treatment